Topics
News
CME/CE
Editorial Advisory Board
Partners
Subscribe
- Case-Based Roundtable
- General Dermatology
- Eczema
- Chronic Hand Eczema
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
- Prurigo Nodularis
- Buy-and-Bill
Article
Limited TIMs?
Author(s):
London -- A report published by Britain's National Prescribing Center saying that Fujisawa's Protopic (tacrolimus) and Novartis' Elidel (pimecrolimus) have only a limited role in the treatment of eczema was intended for general practitioners rather than dermatologists and refers mostly to mild cases treated in primary care settings.
Related Videos
Related Content
